GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc.

$2.07

+0.04 +1.97% today

Price History

Not enough data

Key Stats

Market Cap

43.54M

Avg Volume

176,176

EPS

-$1.17

52W High

$5.18

52W Low

$1.79

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-4.61

P/B Ratio

0.70

EV/EBITDA

-2.87

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(36.2%)

Return on Assets

(10.8%)

Liquidity & Leverage

Current Ratio

11.47

Quick Ratio

11.02

Total Cash

13.76M

Total Debt

About

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.